RecruitingNCT05744466
A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis
A Real-world, Prospective, Observational Study of the Comparative Effectiveness of Deucravacitinib Versus Apremilast in Adults With Plaque Psoriasis - North American Region
Sponsor
Bristol-Myers Squibb
Enrollment
1,500 participants
Start Date
Sep 30, 2022
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of this study is to understand the comparative effectiveness of deucravacitinib versus apremilast in adults with plaque psoriasis.
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- Have been diagnosed with plaque psoriasis by a dermatologist
- Newly initiating an eligible medication for enrollment (i.e., deucravacitinib, apremilast)
- Actively enrolled in the CorEvitas Psoriasis Registry and have documented consent to allow copies of information from the registry be used for research purposes
Exclusion Criteria2
- Participation (current or planned) in an interventional clinical trial (does not include observational registry or study)
- Restart of treatments with the study eligible therapies previously received at any time during the participants' treatment history
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGDeucravacitinib
As prescribed by treating clinician
DRUGApremilast
As prescribed by treating clinician
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05744466
Related Trials
Metabolic Profiling of Immune Responses in Immune-mediated Diseases
NCT048648861 location
Cytokine Expression in Psoriasis Patients With and Without Joint Involvement
NCT053078091 location
Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
NCT047513961 location
A Real-world Study to Evaluate the Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in France (RePhlect)
NCT0670151348 locations
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
NCT0685794241 locations